Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C
<p>Abstract</p> <p>Background</p> <p>The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART.</p> <p>Th...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2002-08-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2334/2/17 |
| _version_ | 1828413342584143872 |
|---|---|
| author | Patruno Savino FA Capelli Anna Maffezzini Elena Brunetti Enrico Zocchetti Cristina Ciappina Valentina Puoti Massimo Sacchi Paolo Bruno Raffaele Malfitano Antonello Filice Gaetano |
| author_facet | Patruno Savino FA Capelli Anna Maffezzini Elena Brunetti Enrico Zocchetti Cristina Ciappina Valentina Puoti Massimo Sacchi Paolo Bruno Raffaele Malfitano Antonello Filice Gaetano |
| author_sort | Patruno Savino FA |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART.</p> <p>The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule.</p> <p>Methods</p> <p>We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA <50 copies/ml in all patients; HCV-RNA 28, 3 × 106 copies/ml.</p> <p>Results</p> <p>At 48 weeks, 10 patients (20%) achieved a biochemical and virological response according to an intention to treat analysis.</p> <p>Twenty four patients (48%) underwent a drop-out mainly by side effects related to overlapping toxicity of interferon and antiretroviral therapy. All the patients, who responded to the treatment, showed a fast relapse one month after the end of treatment.</p> <p>Conclusion</p> <p>Although our results demonstrated a very poor outcome and a bad tolerance to interferon monotherapy, this approach should not be dropped out, mainly in patients at high risk for side effects and in those with cirrhosis who do not tolerate or are at increased risk for the use of ribavirin.</p> |
| first_indexed | 2024-12-10T13:06:49Z |
| format | Article |
| id | doaj.art-15f815647aad4e63bbec7ed83b5f7926 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-12-10T13:06:49Z |
| publishDate | 2002-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-15f815647aad4e63bbec7ed83b5f79262022-12-22T01:47:48ZengBMCBMC Infectious Diseases1471-23342002-08-01211710.1186/1471-2334-2-17Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis CPatruno Savino FACapelli AnnaMaffezzini ElenaBrunetti EnricoZocchetti CristinaCiappina ValentinaPuoti MassimoSacchi PaoloBruno RaffaeleMalfitano AntonelloFilice Gaetano<p>Abstract</p> <p>Background</p> <p>The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART.</p> <p>The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule.</p> <p>Methods</p> <p>We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA <50 copies/ml in all patients; HCV-RNA 28, 3 × 106 copies/ml.</p> <p>Results</p> <p>At 48 weeks, 10 patients (20%) achieved a biochemical and virological response according to an intention to treat analysis.</p> <p>Twenty four patients (48%) underwent a drop-out mainly by side effects related to overlapping toxicity of interferon and antiretroviral therapy. All the patients, who responded to the treatment, showed a fast relapse one month after the end of treatment.</p> <p>Conclusion</p> <p>Although our results demonstrated a very poor outcome and a bad tolerance to interferon monotherapy, this approach should not be dropped out, mainly in patients at high risk for side effects and in those with cirrhosis who do not tolerate or are at increased risk for the use of ribavirin.</p>http://www.biomedcentral.com/1471-2334/2/17HIVHCVCoinfectionInterferonRibavirin |
| spellingShingle | Patruno Savino FA Capelli Anna Maffezzini Elena Brunetti Enrico Zocchetti Cristina Ciappina Valentina Puoti Massimo Sacchi Paolo Bruno Raffaele Malfitano Antonello Filice Gaetano Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C BMC Infectious Diseases HIV HCV Coinfection Interferon Ribavirin |
| title | Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C |
| title_full | Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C |
| title_fullStr | Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C |
| title_full_unstemmed | Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C |
| title_short | Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C |
| title_sort | fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in hiv infected patients with chronic hepatitis c |
| topic | HIV HCV Coinfection Interferon Ribavirin |
| url | http://www.biomedcentral.com/1471-2334/2/17 |
| work_keys_str_mv | AT patrunosavinofa fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT capellianna fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT maffezzinielena fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT brunettienrico fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT zocchetticristina fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT ciappinavalentina fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT puotimassimo fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT sacchipaolo fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT brunoraffaele fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT malfitanoantonello fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc AT filicegaetano fastrelapseandhighdropoutrateof48weeksdailyinterferonmonotherapyinhivinfectedpatientswithchronichepatitisc |